Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
“We are pleased to welcome Greg to our board of directors and chair of
our audit committee. Greg brings a wealth of business, strategic and
financial expertise gained during his accomplished career in the biotech
industry. We look forward to benefitting from his guidance as the
company matures and we continue to advance toward commercialization,”
said
Mr. Perry has served as Audit Committee Chair at
“This is an exciting time to join Kala’s Board of Directors and I am eager to work with the company as it continues to grow and develop innovative treatments for patients with eye diseases,” said Mr. Perry.
About Kala Pharmaceuticals, Inc.
Kala is a
biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to a
corticosteroid designed for ocular applications, resulting in two lead
product candidates. The product candidates are INVELTYS™ (KPI-121 1%)
for the treatment of inflammation and pain following ocular surgery, for
which the
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, that involve substantial risks and
uncertainties including statements regarding the development and
regulatory status of the company's product candidates, including
INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain
following ocular surgery and KPI-121 0.25% for the temporary relief of
the signs and symptoms of dry eye disease. All statements, other than
statements of historical facts, contained in this press release,
including statements regarding the Company’s strategy, future
operations, future financial position, future revenue, projected costs,
prospects, plans and objectives of management, are forward-looking
statements. The words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue” and similar expressions
are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The Company
may not actually achieve the plans, intentions or expectations disclosed
in its forward-looking statements, and you should not place undue
reliance on such forward-looking statements. Actual results or events
could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements as a result of various risks
and uncertainties including, but not limited to: whether our NDA for
INVELTYS will be approved by its PDUFA target action date or at all;
uncertainties inherent in the availability and timing of data from
ongoing clinical trials; expectations for regulatory approvals to
conduct trials or to market products; whether the Company’s cash
resources will be sufficient to fund the Company’s foreseeable and
unforeseeable operating expenses and capital expenditure requirements;
other matters that could affect the availability or commercial potential
of the Company’s product candidates; and other important factors, any of
which could cause the Company’s actual results to differ from those
contained in the forward-looking statements, discussed in the "Risk
Factors" section of the Company’s most recently filed Quarterly Report
on Form 10-Q and other filings the Company makes with the Securities and
Exchange Commission. These forward-looking statements represent the
Company’s views as of the date of this release and should not be relied
upon as representing the Company’s views as of any date subsequent to
the date hereof. The Company does not assume any obligation to update
any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005417/en/
Source:
Investors and Media:
MacDougall Biomedical Communications
Cammy
Duong, 781-591-3443
cduong@macbiocom.com